Ladophar proposes capital increase, business expansion by 2026

Lam Dong Pharmaceutical JSC (Ladophar) is set to hold an extraordinary general meeting in November 2025 to approve several strategic initiatives, including a proposed capital increase and business expansion. The company plans to raise its charter capital from 133,381,670,000 to 187,281,670,000, dividing it into 18,728,167 shares with a par value of 10,000 per share. This capital increase is partly facilitated by a private placement of 5,390,000 shares, raising 59,290,000,000, which has been fully disbursed for the CO2 ultra-critical plant investment.

The company also proposes to expand its business activities to include retail of alcoholic and non-alcoholic beverages, in addition to its core pharmaceutical, medical equipment, and functional food businesses. This diversification aims to enhance competitive capacity and product and service offerings. Ladophar further seeks shareholder approval for a rights issue to existing shareholders, offering 9,364,067 shares at 10,000 each, aiming to raise 93,640,670,000 for project completion and working capital.

Additionally, Ladophar will present a plan to address accumulated losses of 50,655,818,563 by utilizing 24,348,384,362 from its development investment fund and 5,390,000,000 from the share premium reserve generated by the 2025 private placement.